ImaginAb's Biologics Technology Platform Acquired by Telix for Next-Gen Therapeutic Discovery
Funding | Jan 22, 2025 | PR Newswire Cision ImaginAb, Inc.
ImaginAb, Inc., a clinical stage global biotechnology company, has announced the sale of its next-generation therapeutic candidates, proprietary biologics technology platform, and research facility to Telix Pharmaceuticals Limited. Telix intends to utilize ImaginAb's platform to advance its radiotherapeutic technology into new disease areas. Post-transaction, ImaginAb will continue to develop its CD8 ImmunoPET imaging candidate, used in oncology immunotherapy trials, and will also focus on the prostate cancer imaging agent currently in Phase 2 trials. Financial advisory for the transaction was provided by Jefferies LLC and Stifel, Nicolaus & Company. ImaginAb is backed by various investment firms and continues to explore its innovative imaging agents in collaboration with pharmaceutical and biotech partners.
Sectors
- Biotechnology
- Pharmaceuticals
- Medical Imaging
- Venture Capital
Geography
- United States – ImaginAb is based in Inglewood, California, making the U.S. a relevant geography.
- Australia – Telix Pharmaceuticals is an Australian company, making the transaction relevant to Australia.
Industry
- Biotechnology – The main industry relevant to this article as it involves the sale of a biologics technology platform used for drug discovery and development.
- Pharmaceuticals – Telix Pharmaceuticals' involvement and the focus on developing radiopharmaceuticals and imaging agents places the transaction within the pharmaceutical sector.
- Medical Imaging – ImaginAb's focus on imaging agents and technologies like CD8 ImmunoPET and Optical PSMA places it within the medical imaging industry.
- Venture Capital – ImaginAb is backed by venture capital firms, indicating investment activities relevant to the venture capital industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ImaginAb, Inc. | Target Company | Company | A biotechnology company specializing in radiopharmaceuticals and imaging agent products. |
| Telix Pharmaceuticals Limited | Bidding Company | Company | An Australian pharmaceutical company listed on ASX and Nasdaq, focusing on radiopharmaceuticals. |
| Jefferies LLC | Financial Advisor | Company | Served as a financial advisor to ImaginAb on the transaction. |
| Stifel, Nicolaus & Company, Incorporated | Financial Advisor | Company | Also served as a financial advisor to ImaginAb on the transaction. |
| Dr. Anna Wu | Founder | Person | Founder of ImaginAb, commented on the significance of the transaction. |